NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-07-23
Reading HROW? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment is speculative growth, as HROW is currently loss-making but operates in a sector with potential tailwinds. The company's recent financial performance shows strength, but management execution has been volatile, creating uncertainty in the multi-year view.
The market seems to price in a durable premium compared to peers, indicating high expectations despite the company's current losses. There is an expectations gap, suggesting that investors may not fully account for the risks and volatility associated with HROW.
Management has set ambitious revenue and EBITDA targets for 2026, but recent performance indicates a challenging path ahead. The elevated risk of missing earnings in the near term adds to the uncertainty surrounding the company's ability to meet its goals.
The long-term thesis hinges on the performance of sector bellwethers like HLN, TEVA, and ZTS, which could influence HROW's trajectory. Additionally, the company's ability to execute on its revenue and EBITDA targets will be crucial in determining its future performance.
Over the next 1 to 3 years, HROW's performance will depend on external sector dynamics and internal execution. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Earnings results will provide insight into revenue and EBITDA progress. It is a key moment for investors.
Confirms one read:Earnings report shows revenue and EBITDA meet or beat guidance.
Confirms the other:Earnings report shows revenue and EBITDA far below guidance.
Why it matters: If earnings miss again, people will worry about the company's growth plans and how they work.
Confirms:Q2 2026 earnings report shows a loss similar to Q1.
Disproves:Q2 2026 earnings report shows a profit or smaller loss.
Why it matters: If the company misses earnings again, it may have bigger money problems.
Confirms:A press release confirming another earnings miss.
Disproves:Earnings meet or exceed expectations.
Why it matters: If revenue growth slows, it may signal deeper issues in Harrow's business model.
Confirms:Revenue growth drops below its median for the sector.
Disproves:Revenue growth remains stable or improves.
Why it matters: This will indicate if the company can achieve its full-year revenue target. It shows management's confidence.
Confirms one read:Management confirms the Q2 revenue target of $71M-$81M.
Confirms the other:Management cuts the Q2 revenue target.
Why it matters: If the health care sector grows faster, it could help Harrow improve its performance.
Confirms:Health care sector revenue growth is speeding up again. It is now over 10% year over year.
Disproves:Sector revenue growth is slowing down. It is now below 10% year over year.
Why it matters: This target is key for showing financial health. It indicates if the company can improve its losses.
Confirms:Adjusted EBITDA was $80M or more.
Disproves:Adjusted EBITDA was less than $80M.
Why it matters: The earnings report will provide updates on revenue and losses. Investors will look for signs of improvement.
Confirms one read:An announcement of the next earnings report date within the next month.
Confirms the other:No date for the earnings report has been announced. This shows ongoing uncertainty.
Why it matters: This revenue range is crucial for Harrow to stay on track for its annual goals. A strong Q2 would show recovery after a weak Q1.
Confirms:Q2 2026 revenue reported between $71 million and $81 million.
Disproves:Q2 2026 revenue falls below $71 million.
Why it matters: Improving Adjusted EBITDA is key for Harrow to meet its annual target of $80M-$100M. It shows better cost management.
Confirms:Adjusted EBITDA for Q2 2026 shows a big gain from Q1's loss of $12.7 million.
Disproves:Adjusted EBITDA stays negative or gets worse in Q2 2026.
Why it matters: VEVYE's growth is vital for Harrow's revenue. Continued strong demand supports the company's revenue guidance.
Confirms:VEVYE prescriptions go up from Q1 to Q2 2026.
Disproves:VEVYE prescriptions decline or stagnate in Q2 2026.
